Patents by Inventor Kenji Morishima
Kenji Morishima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220054520Abstract: Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.Type: ApplicationFiled: February 26, 2020Publication date: February 24, 2022Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Kenji MORISHIMA, Hiroyuki ASADA, Yusuke MOMOKAWA, Asuka KAMIMURA, Kenichi ENDO
-
Publication number: 20210000844Abstract: Provided is an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, the cationic polymer being at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt-acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soy protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, a dimethyldiacrylammonium chloride homopolymer, an adipic acid-dimethylaminohydroxypropyldiethylenetriamine copolymer, an adipic acid-epoxypropyldiethylenetriamine copolymer and an acrylamide-?-methacryloyloxyethyltrimethylammoniummethyl sulfate copolymer.Type: ApplicationFiled: February 27, 2019Publication date: January 7, 2021Applicant: Santen Pharmaceutical Co., Ltd.Inventors: Kyohei TAKAHASHI, Hiroyuki ASADA, Asuka KAMIMURA, Kenji MORISHIMA, Yusuke MOMOKAWA, Kenichi ENDO
-
Publication number: 20180353518Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.Type: ApplicationFiled: August 21, 2018Publication date: December 13, 2018Applicants: Santen Pharmaceutical Co., LTD., Asahi Glass Company, LimitedInventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
-
Publication number: 20160106757Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.Type: ApplicationFiled: December 28, 2015Publication date: April 21, 2016Applicants: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITEDInventors: Kenji MORISHIMA, Akio KIMURA, Hiroyuki ASADA, Masayuki UMEDA, Mitsuaki KUWANO
-
Publication number: 20070248697Abstract: A method of preventing a lowering of concentration of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? isopropyl ester, the prostaglandin derivative being contained in an ophthalmic solution as an active ingredient. The method including (i) adding to the ophthalmic solution a nonionic surfactant to inhibit the prostaglandin derivative from being adsorbed to a container which contains the ophthalmic solution, the container being made of a resin and (ii) adding to the ophthalmic solution an antioxidant to inhibit decomposition of the prostaglandin derivative.Type: ApplicationFiled: June 26, 2007Publication date: October 25, 2007Applicants: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITEDInventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
-
Patent number: 7147844Abstract: A purpose of the present invention is to remove dryness and unpleasantness in eyes of contact lens wearers and to obtain favorable moist feel and wearing feel by stabilizing a lacrimal fluid layer on the surface of eyeballs of the wearers. By using an ophthalmic composition containing polyvinyl pyrrolidone, the lacrimal fluid layer existing on ionic contact lenses can be stabilized via adsorption of polyvinyl pyrrolidone on the ionic contact lenses. By adding a viscosity-increasing agent to the ophthalmic composition, the lacrimal fluid layer can be maintained in a stable state over a long period of time.Type: GrantFiled: December 26, 2000Date of Patent: December 12, 2006Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Takashi Hamano, Kenji Morishima, Norihisa Hatano
-
Publication number: 20050119299Abstract: Additives which enhance the antiseptic effect of a cationic antiseptic agent are added to ophthalmic solutions containing a compound having the chemical structure of the following general formula (I). The antimicrobial effect of the ophthalmic solutions containing a compound having the chemical structure of the general formula (I) and a cationic antiseptic agent is markedly increased by adding a basic amine compound to the solutions. In the general formula (I), R1 is a group of the following structural formula (Ia), (Ib), (Ic), (Id), (Ie) or (If).Type: ApplicationFiled: September 2, 2004Publication date: June 2, 2005Applicant: SANKYO COMPANY, LIMITEDInventors: Takeshi Uneda, Akio Kimura, Kenji Morishima
-
Publication number: 20050106265Abstract: A method of preserving an aqueous liquid preparation comprising adding a preservative comprising boric acid and/or borax, ethylenediaminetetraacetic acid or a salt thereof and polyvinyl pyrrolidone, and optionally a cellulosic polymer to an aqueous liquid preparation.Type: ApplicationFiled: December 13, 2004Publication date: May 19, 2005Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Kenji Morishima, Norihisa Hatano
-
Publication number: 20040097592Abstract: An object of the present invention is to formulate prostaglandin derivatives which are hardly soluble in water and liable to be adsorbed to a resinous container and prostaglandin derivatives which are liable to decompose when dissolved in water in ophthalmic solutions. Solubility of the prostaglandin derivatives in water is improved and the adsorption thereof to the resinous container can be remarkably inhibited by adding a nonionic surfactant such as polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 to the ophthalmic solutions. The decomposition of the prostaglandin derivatives can be remarkably inhibited by adding an antioxidant such as disodium ethylenediaminetetraacetate or dibutylhydroxytoluene.Type: ApplicationFiled: March 12, 2003Publication date: May 20, 2004Inventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
-
Publication number: 20030152631Abstract: An object of the present invention is to provide safe preservatives by combining components widely used as additives of aqueous liquids. Preferred preservatives are obtained by combining boric acid and/or borax, ethylenediaminetetraacetic acid or a salt thereof and polyvinyl pyrrolidone. Preservation effects can be enhanced by further combining cellulosic polymers with the preservatives.Type: ApplicationFiled: December 16, 2002Publication date: August 14, 2003Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Kenji Morishima, Norihisa Hatano
-
Publication number: 20030021829Abstract: A purpose of the present invention is to remove dryness and unpleasantness in eyes of contact lens wearers and to obtain favorable moist feel and wearing feel by stabilizing a lacrimal fluid layer on the surface of eyeballs of the wearers. By using an ophthalmic composition containing polyvinyl pyrrolidone, the lacrimal fluid layer existing on ionic contact lenses can be stabilized via adsorption of polyvinyl pyrrolidone on the ionic contact lenses. By adding a viscosity-increasing agent to the ophthalmic composition, the lacrimal fluid layer can be maintained in a stable state over a long period of time.Type: ApplicationFiled: June 24, 2002Publication date: January 30, 2003Inventors: Takashi Hamano, Kenji Morishima, Norihisa Hatano
-
Patent number: 6288049Abstract: A fluorometholone ophthalmic suspension containing fluorometholone as an active ingredient, wherein a cellulosic polymer, such as hydroxypropylmethylcellulose or methylcellulose, and a nonionic surfactant, such as polysorbate 80, are added thereto to increase the redispersibility of the fluorometholone. The amount of the cellulosic polymer is preferably 0.0001 to 0.003 (W/V) %, and the amount of the nonionic surfactant is preferably 0.0001 to 0.5 (W/V) %. The fluorometholone ophthalmic suspension has excellent redispersibility and hardly forms aggregates.Type: GrantFiled: July 13, 2000Date of Patent: September 11, 2001Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Kenji Morishima, Kazufumi Shiotani